Promises and challenges of targeting inflammation to treat cardiovascular disease: the post-CANTOS era
- PMID: 31504422
- DOI: 10.1093/eurheartj/ehz586
Promises and challenges of targeting inflammation to treat cardiovascular disease: the post-CANTOS era
Comment on
-
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.Eur Heart J. 2020 Jun 14;41(23):2153-2163. doi: 10.1093/eurheartj/ehz542. Eur Heart J. 2020. PMID: 31504417 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
